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with the soluble TNF-α receptor etanercept.
However, researchers in Chicago report that
four female patients developed symptoms
of SLE during treatment with etanercept,
highlighting the need for caution in the use
of this drug and the need to clarify the
prevalence and pathogenesis of the these
responses (The Lancet 359, 579–580). SW
CD40 ligand sheds LIGHT on
graft-versus-host disease
Graft-versus-host disease (GVHD) is caused
by alloreactive immune responses and is a
major complication of bone marrow
transplantation. Pharmacological agents
with immunosuppressive actions prevail as
major therapeutic interventions, but they
require prolonged administration that can
result in general immune suppression.
Previous studies have shown that blockade
of the T cell costimulatory molecule LIGHT
by soluble lymphotoxin receptor-Ig (LTR-Ig)
ameliorates lethal GVHD in a mouse model.
Researchers at the Mayo Clinic in the USA
now report that infusion of a monoclonal
antibody against CD40 ligand further
increases the efficacy of LTR-Ig, leading to
complete prevention of GVHD. Alloantigen-
specific cytotoxic T-lymphocytes become
anergic and persist in the tolerized mice as a
result of costimulatory blockade and tranfer
of anergic CTLs to recipient mice fails to
induce GVHD. The study provides a
potential new and exciting approach for the
prevention of lethal GVHD (J. Clin. Invest.
109, 549–557).  SW
One AIDS battle over
Although the fight against AIDS is still
raging, at least one battle has ended with
the announcement in February that the
researchers Robert Gallo and Luc
Montagnier are to collaborate on
developing AIDS vaccines for Africa. The
two plan to merge their vaccine approaches
more than almost two decades after their
famous falling-out over accreditation for the
discovery of HIV and the resultant blood
test. Gallo’s team focuses on tacking various
HIV genes into Salmonella, whereas
Montagnier concentrates on making
vaccines from HIV proteins gag, tat and nef.
Montagnier, who now heads the World
Foundation for AIDS Research and
Prevention cites one reason for the
collaboration: ‘If we join our efforts, it will be
more credible for fund-raising.’ Testing of
Gallo’s vaccines could be speeded up by
tapping into data produced from
Montagnier’s recent testing sites in
Côte d’Ivoire and Cameroon. However,
within the HIV research community, there is
doubt as to the substance of potential
collaborations, because Montagnier, for
example, still contends that HIV relies on
cofactors to cause disease, an idea that
Gallo contends. Stay tuned for
developments in this high-profile
relationship (Science 295, 1441–1442).  AL
Can cytokines shrink babies?
Growth in utero has a profound effect on the
expression of genetic potential. Its
retardation can impede neurological
development and is associated with higher
neonatal death rates, early onset diabetes
and cardiac disease. Levels of placental
cytokines have been found to relate to birth
weight in groups of Swedish infants. PCR
analysis of placentae collected from groups
of infants showed a reduction in the IL-10
mRNA in situations of intrautine growth
retardation, without any of the cytokine
changes suggestive of hypoxia or
inflammation, which are other causes of
growth retardation. It is possible that this is
a primary event, resulting in a bias towards
Th1 cytokine production. This in turn might
lead to inadequate placental support and
diminished growth of the fetus (Ped. Res.
51, 201–206).  CM
Tolls for viruses
Of the ten members of the toll-like receptor
(TLR) family, ligands have been identified for
only six. Several TLRs, including TLR7, do
not have clearly described roles.
Investigation into the antiviral imidazoquines
have shown that they activate the immune
system as a crucial part of their activity. Mice
defective in TLR7 expression, or in the
signalling components used by TLRs, do not
show either immune activation or antiviral
activities when exposed to these
compounds, suggesting a link between TLR7
and viral defences. The exact ligands
involved need to be determined, as do the
connections between TLR7 and interferon-α
production. Therapeutically, this offers new
vistas for antiviral adjuvants that can exploit
TLRs; imidazoquines could become
pioneering compounds that are crucial to
improved vaccination programs (Nat.
Immunol. 3, 196–200).  CM
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Immunoneutralization
and anti-idiotype
production: two-sided
applications of leptin
The neuroendocrine and immune systems
are linked through a complex
bi-directional network, in which
hormones modify immune function, and
the immune system, through the action of
cytokines, affects neuroendocrine
responses involved in the maintenance of
body homeostasis. The adipocyte-derived,
peptide hormone leptin is a pleiotropic
molecule belonging to the helical cytokine
family. On pp. 182–187, Matarese et al.
suggest the possibility of new leptin-
based therapeutic strategies for the
treatment of both infection and
autoimmune disease.
It is believed generally that the
primary physiological function of leptin is
to coordinate metabolic, endocrine and
behavioral responses to changing energy
status. The level of secreted leptin is
proportional to body-fat level [1], and
through its actions on hypothalamic
centers, leptin suppresses food intake and
increases energy expenditure. Besides its
actions on appetite and metabolism, leptin
is capable of modulating the immune
response also. Functional leptin receptors
are found on human monocytes [2] and
exogenous leptin has been found to
up-regulate macrophage phagocytosis 
and the production of proinflammatory
cytokines [3], as well as enhance T-helper-
cell responses [4].
The production of leptin is influenced by
nutritional status, with malnutrition or
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starvation resulting in both reduced
circulating leptin levels and suppressed
immune function. Animals with a
deficiency in the ability to produce leptin [5]
or genetic defects in the leptin receptor [6]
are markedly hyperphagic and obese, and
have impaired cell-mediated immunity [7].
The administration of exogenous leptin
reduces hyperphagia, induces weight loss
[8] and reverses starvation-induced
immunosuppression [4]. By contrast, too
much leptin seems to increase
susceptibility to autoimmune reactions.
Female mice, which have elevated leptin
levels compared with males, are more
susceptible to disease in autoimmune
models, whereas leptin treatment
reverses male resistance to autoimmune
diseases [9].
Perhaps, leptin-based immunotherapy
could be used in synergy with other
strategies to treat both infection and
autoimmune disease. That is, antileptin
therapies might reduce or block the
activation and priming of pathogenic
T-cell populations in autoimmune
diseases [9], whereas leptin agonists could
be used to augment the immune system
and reduce susceptibility to infection in
undernourished and immunosuppressed
individuals. A novel proposal is the use
and/or induction of expression of
antibodies to either immunoneutralize or
serve as surrogate ligands. Antibodies can
reduce circulating hormone levels,
thereby reducing some in vivo functions
[10], whereas anti-idiotype antibodies,
carrying an ‘internal image’of an epitope
of the external antigen (i.e. leptin) [11],
have the potential to transduce signals
upon binding to their receptors. A leptin
anti-idiotype antibody can reproduce the
potentiating effects of leptin on
lymphocyte proliferation (Fig. 1), as well
as mimic leptin’s central effects on food
intake and thermogenesis [12].
Alterations in the leptin-mediated
immune–neuroendocrine homeostatic
network result in pathophysiological
conditions, suggesting an
immunomodulatory role for leptin in
susceptibility to infection and
autoimmunity (see pp. 182–187). The
demonstration that immunization with a
monoclonal anti-leptin antibody reduces
leptin biological activity (Fig. 2a),
whereas leptin anti-idiotypes exert some
of the same in vivo effects as leptin
(Fig. 2b), suggests that
immunomanipulation might be a
promising approach to reducing
susceptibility to infection and
autoimmunity, as well as regulating
body-weight homeostasis. With the
number of undernourished people in the
world remaining high and an estimated
quarter of all obese people being leptin-
deficient [13], the effects of leptin on
immunocompetence proposed by
Matarese et al. suggest that a very large
population could benefit potentially from
leptin therapy, and humanized antibodies
might be potential therapeutic agents for
several leptin-related disorders.
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Fig. 1. Anti-idiotype antibody (Ab) mimics the
enhancing effect of leptin on lymphocyte proliferation.
The proliferative response of lymphocytes isolated from
spleen was determined using the [3H]-thymidine
method after 72 hours of culture in RPMI culture
medium with lipopolysaccharide (LPS) from Escherichia
coli (50 µg ml−1), LPS plus leptin (1.7 µg ml−1) or LPS plus
anti-idiotype antibody (1.7 µg ml−1). The addition of
leptin or anti-idiotype antibody to LPS led to a 75% or
83% increase in lymphocyte proliferation, respectively.
A nonparametric Friedman’s test was used (P <0.05;
n = 6) to analyze the data.
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Fig. 2. Acute changes in colonic temperature after (a) intravenous anti-leptin antibody administration in mice [10] or
(b) intracerebroventricular administration of anti-idiotype in rats [12].
